Home > Healthcare > Medical Devices > Diagnostic Devices > STD Diagnostics Market

STD Diagnostics Market Trends

Report ID: GMI8292
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

STD Diagnostics Market Trends

There is increasing awareness among healthcare providers and patients regarding the benefits of utilizing STD diagnostics, as it facilitates prompt treatment initiation. Through early identification of infected individuals, screening programs play a crucial role in preventing the further spread of STDs within the community.

Thus, this awareness has led to greater adoption of STD diagnostics among healthcare professionals and patients alike.
Furthermore, ongoing advancements in technology have resulted in the creation of more sophisticated and user-friendly devices for sexually transmitted diseases (STDs).
For instance, Abbott's Alinity m STI Assay, approved by the Food and Drug Administration (FDA) in May 2022, is a multiplex test capable of simultaneously detecting and distinguishing four prevalent STDs.
These technological enhancements improve the efficiency of diagnostic tests, increase patient compliance with testing protocols, and diminish the likelihood of adverse effects associated with STD treatments.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of STD diagnostics reached USD 13.8 billion in 2023 and is set to cross USD 25.7 billion by 2032, owing to the rising prevalence of sexually transmitted diseases, and a growing need for effective management & treatment options.

The consumables segment is estimated to surpass USD 18.3 billion by 2032, due to their ability to comprehensive management of STDs by facilitating accurate diagnosis, prompt treatment initiation, preventive measures, and patient education.

North America market accounted for USD 5.6 billion in 2023, backed by a sophisticated healthcare infrastructure, rising prevalence of STDs, rapid technological advancement, and substantial healthcare spending in the region.

Abbott Laboratories, Becton, Dickinson, and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN N.V., Seegene Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech plc.